In line with these findings, significantly higher plasma levels of inflammatory and antitumorigenic cytokines TNF-α (p < 0.05, Figure 2(l)) and IFN-γ (p < 0.05, Figure 2(m)) and significantly lower plasma levels of immunosuppressive cytokines TGF-β (p < 0.05, Figure 2(n)) and IL-10 (p < 0.05, Figure 2(o)) were observed in B16F10+MSC1d-treated mice, indicating that MSCs, transplanted during the initial phase of melanoma growth, enhanced antitumor immune response in melanoma-bearing animals. This evidence concerns the gene IL10 and melanoma.